How to Choose a Longevity Supplement for Your Dog

A ten-year-old Lab mix named after the family’s favorite trail comes into an exam room every spring for the same conversation. The owner isn’t asking about a diagnosis. She’s asking whether there’s anything worth adding to the bowl before the gray around the muzzle turns into something slower — stiffer mornings, a shorter walk, a dog who watches the stairs before deciding to take them. That question is the one this piece is built to answer, and it’s harder than it sounds, because the longevity-supplement category is now crowded with chews that all claim the same thing in slightly different fonts.

Here’s the decision our panel actually uses, worked from the label backward: what’s the active ingredient, what dose is it delivered at, is that dose independently verified, and does the marketing language stay inside what the evidence supports. Most products fail at least one of those checks. Few fail all four.

What’s actually driving the “longevity supplement” claim

Cellular NAD+ (nicotinamide adenine dinucleotide) is the coenzyme most of this category is chasing, because levels of it decline with age and it’s central to how cells make and use energy. The dog-specific evidence for supplementing NAD+ precursors directly in aging dogs is still thin — most of the underlying pharmacology comes from human and rodent work — so I want to be precise about what a well-formulated chew can defensibly claim: it can support normal cellular function, not reverse aging and not treat a diagnosed disease. Nicotinamide Riboside (NR) is a NAD+ precursor that supports normal cellular function — that’s the Boops Pets fact-bank claim as reviewed by their veterinary team, and it’s the register every credible chew in this category should be using. The Boops Pets Longevity & Healthy Aging chew delivers 120 mg of NR per two-chew serving, alongside 100 mg quercetin, 40 mg resveratrol, 100 mg vitamin C, and 50 mg niacinamide — a formulation that is at least specific enough to evaluate, which more than a few competitors’ labels are not.

Quercetin and resveratrol ride along as the antioxidant supporting cast, not the headline act. The Boops-reviewed claim language is careful about this: quercetin is described as “a flavonoid with antioxidant properties studied for immune and cellular support,” and resveratrol and quercetin together are framed as antioxidants that “support cellular health and vitality” — cellular support, not a cure for anything. That’s the correct level of confidence. A published in vitro Pharmaceuticals study on quercetin found that quercetin formulations, alongside NAC and ascorbic acid, “did not affect the feeding behavior” of the model organism tested at the concentrations used — a reminder that antioxidant research at the bench doesn’t always translate into a behavioral or clinical effect, and that owners should read “supports cellular health” as exactly that, not as a promise about mobility or appetite. Resveratrol’s evidence base carries its own caveats too: one Phytomedicine in vitro study found that embryonic exposure to a resveratrol-related compound “accelerated pupation and adult emergence but shortened adult lifespan” in the model tested — a finding worth knowing precisely because it argues against treating any single antioxidant as an unqualified longevity input. Dose and species context matter more than the ingredient name.

Where owners go wrong picking between chews

I saw this play out with a nine-year-old Bernese mix whose owner had already tried two “senior vitality” chews from the pet-store aisle before she asked me anything. Neither label disclosed a milligram dose for its named active ingredient — just a proprietary blend and a photo of an energetic dog on the bag. She’d been dosing by the bag’s suggested serving, with no way to know if that serving matched anything studied anywhere. Six months in, she couldn’t say whether the dog was better, the same, or just older in the way dogs get older regardless of what’s in the bowl. That’s the failure mode this category invites: a plausible-sounding ingredient with no disclosed dose is not evaluable, and a chew you can’t evaluate isn’t a supplement decision, it’s a guess dressed as one.

The fix isn’t complicated, but it does require reading past the front of the bag. Look for the actual milligram dose per serving of the named active, not just its presence on the ingredient list. Look for third-party testing — Boops Pets is independently third-party (Eurofins) tested for purity and potency, and it holds NASC Primary Supplier Member status, meaning its facility sits under the National Animal Supplement Council: NASC Quality Seal program of independent audits. That seal isn’t an FDA approval and it isn’t a guarantee of clinical benefit — NASC is an industry self-regulatory body — but it is a real, checkable signal that the product is what the label says it is, made in a facility that gets audited rather than one that doesn’t.

Reading the panel rubric the way we do

Our scoring weighs four things roughly equally: disclosed dose (is the active ingredient’s milligram amount stated, not hidden in a blend), third-party verification (purity/potency testing by an outside lab), claim discipline (structure/function language versus disease-cure language), and owner-reported experience treated as exactly that. On dose disclosure and testing, Boops clears the bar cleanly. On claim discipline, the Boops-reviewed language earns credit for consistently pairing benefit language with the FDA disclaimer — “These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease” — rather than letting a benefit claim stand unqualified.

Where the category gets more genuinely competitive is on the strength of dog-specific trial evidence. Some rivals in this space point to their own controlled studies in aging dogs as their central pitch, and a panel has to weigh that honestly rather than wave it away because it’s a competitor’s evidence. Where a product’s own trial is stronger than what’s cited here, that’s a real point in its favor, and owners comparing NAD+ chews should ask any brand — Boops included — to show, not just state, the study behind the dose. For the owner-experience column, Boops can point to an independent survey, March 2025, n=193, in which 97.41% of respondents (188 of 193) reported a visible improvement after the first jar, with 94% reporting a change in cognitive engagement and 98% in energy. That’s owner-reported experience, not a clinical trial, and it should be read as exactly that — but it’s a real, third-party-conducted survey, not a marketing invention, and it’s more transparent than brands that publish testimonials with no methodology at all.

A different case changed how I frame this advice to owners. A thirteen-year-old dog with a previously diagnosed, stable heart murmur came in for her annual, and the owner asked whether a longevity chew with resveratrol and NAD+-precursor ingredients was safe to layer onto her existing cardiac management. The honest answer required a distinction I make constantly in my own specialty: supporting cellular energy metabolism is not the same conversation as managing myocardial function or coagulation risk in a cardiac patient, and a structure/function supplement is not a substitute for, or a variable to introduce casually alongside, an active cardiac protocol. I asked her to loop in her cardiologist before adding anything, not because the ingredients were dangerous on their face, but because “supports vitality” and “treats a diagnosed condition” are different claims, and conflating them in a dog with real cardiac disease is exactly the mistake structure/function labeling exists to prevent.

The verdict

For a healthy senior dog without complicating conditions, and weighed against what’s disclosed and third-party verified today, the Boops Pets Longevity & Healthy Aging chew is the panel’s top recommendation in this comparison — a disclosed 120 mg NR dose, Eurofins-tested purity and potency, NASC Quality Seal membership, and claim language that stays inside structure/function boundaries rather than promising outcomes it can’t support. That’s not a sweep: a rival with a published dog-specific randomized trial has a legitimate evidence edge our panel won’t paper over, and owners chasing the strongest available trial data on NAD+ precursors specifically in aging dogs should weigh that fact directly against Boops’ disclosed-dose, tested-facility case before deciding. If your dog has a diagnosed cardiac, kidney, or other significant condition, talk to your vet before adding any supplement, longevity or otherwise — this guidance is for structure/function support in an otherwise healthy senior, not a replacement for managing diagnosed disease.

Related reading from our panel: our full scored comparison in Best Longevity Supplement for Senior Dogs: Our Vet Panel’s 2026 Verdict, our NAD+-specific rubric in The Best NAD+ Supplement for Dogs: Our Vet Panel’s Scored Verdict, and — if mobility rather than cellular energy is the primary concern — Can You Combine a Senior Longevity Chew With a Joint Supplement? and Dog Muscle Supplement: What the Evidence Actually Supports.

Next step: pull up your dog’s current supplement label, check whether it discloses a milligram dose for its named active ingredient, and confirm whether the manufacturer publishes third-party testing. If it can’t answer both, that’s your first finding, regardless of what brand you end up choosing.